Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 160, Issue 5, 2009, Pages 847-853

  Diamanti Kandarakis, Evanthia ^a   Piouka, Athanasia ^b   Livadas, Sarantis ^a   Piperi, Christine ^a   Katsikis, Ilias ^b   Papavassiliou, Athanasios G ^a   Panidis, Demetrios ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; MUELLERIAN INHIBITING FACTOR;

ADULT; ANOVULATION; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLLICULAR PHASE; GRANULOSA CELL; HORMONE BLOOD LEVEL; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; WOMEN'S HEALTH; BLOOD; BODY WEIGHT; CASE CONTROL STUDY; COHORT ANALYSIS; ECHOGRAPHY; OVARY; OVULATION;

ADULT; ANOVULATION; ANTI-MULLERIAN HORMONE; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OVARY; OVULATION; POLYCYSTIC OVARY SYNDROME; THINNESS; YOUNG ADULT;

EID: 65549168984     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0510     Document Type: Article

References (50)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 1997 18 774-800.
2. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Reviews in Molecular Medicine 2008 10 e3.
3. Chang WY, Knochenhauer ES, Bartolucci AA & Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertility and Sterility 2005 83 1717-1723.
4. Panidis DK, Rousso DH, Kourtis AI & Papathanasiou KV. Could the theory of chaos contribute to the interpretation of pathogenesis of polycystic ovary syndrome? Clinical and Experimental Obstetrics and Gynecology 2003 30 187-189.
5. Franks S, Stark JE & Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Human Reproduction Update 2008 14 367-378.
6. La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A & De Leo V. Mullerian inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertility and Sterility 2004 82 970-972.
7. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC & Themmen AP. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Molecular Human Reproduction 2004 10 77-83.
8. Pigny P, Jonard S, Robert Y & Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 941-945.
9. Fallat ME, Siow Y, Marra M, Cook C & Carrillo A. Mullerian inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertility and Sterility 1997 67 962-965.
10. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S & Dewailly D. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. Journal of Clinical Endocrinology and Metabolism 2003 88 5957-5962.
11. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S & Mason H. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. Journal of Clinical Endocrinology and Metabolism 2007 92 240-245.
12. Dewailly D, Catteau-Jonard S, Reyss AC, Maunoury-Lefebvre C, Poncelet E & Pigny P. The excess in 2-5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome. Human Reproduction 2007 22 1562-1566.
13. Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS & Ho HN. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Human Reproduction 2008 23 952-957.
14. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar RT, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed AJ & Themmen AP. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001 142 4891-4899.
15. Agarwal A, Gupta S & Sharma RK. Role of oxidative stress in female reproduction. Reproductive Biology and Endocrinology 2005 3 28.
16. Tatone C, Carbone MC, Falone S, Aimola P, Giardinelli A, Caserta D, Marci R, Pandolfi A, Ragnelli AM & Amicarelli F. Age-dependent changes in the expression of superoxide dismutases and catalase are associated with ultrastructural modifications in human granulosa cells. Molecular Human Reproduction 2006 12 655-660.
17. Fenkci V, Fenkci S, Yilmazer M & Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertility and Sterility 2003 80 123-127.
18. Kwintkiewicz J, Spaczynski RZ, Foyouzi N, Pehlivan T & Duleba AJ. Insulin and oxidative stress modulate proliferation of rat ovarian theca-interstitial cells through diverse signal transduction pathways. Biology of Reproduction 2006 74 1034-1040.
19. Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I & Panidis D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethylarginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008 196 958-965.
20. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991 40 405-412.
21. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW & Lyons TJ. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. Journal of Clinical Investigation 1993 91 2470-2478.
22. Singh R, Barden A, Mori T & Beilin L. Advanced glycation end products: a review. Diabetologia 2001 44 129-146.
23. Diamanti-Kandarakis E, Piperi C, Kalofoutis A & Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology 2005 62 37-43.
24. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K & Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clinical Endocrinology 2007 66 103-109.
25. Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG & Panidis D. Increased serum advanced glycation end products is a distinct finding in lean women with PCOS. Clinical Endocrinology 2008 69 634-641.
26. Peppa M, Uribarri J & Vlassara H. Aging and glycoxidant stress. Hormones 2008 7 123-132.
27. Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, Papavassiliou AG & Duleba AJ. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochemistry and Cell Biology 2007 127 581-589.
28. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, Kandaraki E, Levidou G, Papalois A, Patsouris E & Papavassiliou AG. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. Journal of Molecular Medicine 2007 85 1413-1420.
29. Rotterdam Consensus. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47.
30. Hamilton-Fairley D & Taylor A. Anovulation. BMJ 2003 327 546-549.
31. Diamanti-Kandarakis E, Piperi C, Alexandraki K, Katsilambros N, Kouroupi E, Papailiou J, Lazaridis S, Koulouri E, Kandarakis HA, Douzinas EE, Creatsas G & Kalofoutis A. Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 2006 55 494-500.
32. Visser JA, de Jong FH, Laven JS & Themmen APN. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 2006 131 1-9.
33. Chu MC, Carmina E, Wang J & Lobo RA. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B. Fertility and Sterility 2005 84 1685-1688.
34. Catteau-Jonard S, Soazik PJ, Leclerc A, Gonzales J, Dewailly D & di Clemente N. Anti-Mullerian hormone, its receptor, FSH receptor and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 4456-4461.
35. Laven JS, Mulders AG, Visser JA, Themmen APN, De Jong FH & Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. Journal of Clinical Endocrinology and Metabolism 2004 89 318-323.
36. Eldar-Geva T, Margalioth EJ, Gal M, Ben-Chetrit A, Algur N, Zylber-Haran E, Brooks B, Huerta M & Spitz IM. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Human Reproduction 2005 20 1814-1819.
37. di Clemente N, Goxe B, Remy JJ, Cate RL, Josso N, Vigier B & Salesse R. Inhibitory effect of AMH upon aromatase activity and LH receptors of granulosa cells of rat and porcine immature ovaries. Endocrine 1994 2 553-558.
38. Grossman MP, Nakajima ST, Fallat ME & Siow Y. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertility and Sterility 2008 89 1364-1370.
39. Josso N, Racine C, di Clemente N, Rey R & Xavier F. The role of anti-Mullerian hormone in gonadal development. Molecular and Cellular Endocrinology 1998 145 3-7.
40. Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M & Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biology of Reproduction 1999 61 353-357.
41. Agarwal A & Allamaneni SS. Role of free radicals in female reproductive diseases and assisted reproduction. Reproductive Biomedicine Online 2004 9 338-347.
42. Gonzalez F, Rote NS, Minium J & Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 336-340.
43. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM & De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002 105 816-822.
44. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, Clissa C, Ciabattoni G, Consoli A & Davì G. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radical Biology and Medicine 2007 43 511-518.
45. Tsai-Turton M & Luderer U. Opposing effects of glutathione depletion and follicle stimulating hormone on reactive oxygen species and apoptosis in cultured preovulatory rat follicles. Endocrinology 2006 147 1224-1236.
46. Tatone C, Amicarelli F, Carbone MC, Monteleone P, Caserta D, Marci R, Artini PG, Piomboni P & Focarelli R. Cellular and molecular aspects of ovarian follicle ageing. Human Reproduction Update 2008 14 131-142.
47. Lund SA, Murdoch J, Van Kirk EA & Murdoch WJ. Mitogenic and antioxidant mechanisms of estradiol action in preovulatory ovine follicles: relevance to luteal function. Biology of Reproduction 1999 61 388-392.
48. Valdez KE, Cuneo SP & Turzillo AM. Regulation of apoptosis in the atresia of dominant bovine follicles of the first follicular wave following ovulation. Reproduction 2005 130 71-81.
49. Sabuncu T, Vural H, Harma M & Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clinical Biochemistry 2001 34 407-413.
50. Duleba AJ, Foyouzi N, Karaca M, Pehlivan T, Kwintkiewicz J & Behrman HR. Proliferation of ovarian theca-interstitial cells is modulated by antioxidants and oxidative stress. Human Reproduction 2004 19 1519-1524.